Preliminary Program subject to change
Pharmacokinetics in Drug Discovery and Development
Presentation Type	Oral
Summary Statement
Presider:	Dennis Scott, Pfizer, Groton, CT
Introductory Remarks Nonspecific brain binding as an indirect tool to assess CNS penetration Tristan Maurer, Pfizer, Groton, CT Human dose projection from pre clinical CNS models: Lundbeck experience Gamini Chandrasena, Lundbeck US Research, Paramus, NJ Break Application of Physiologically-Based Models in Drug Discovery and Development David Plowchalk, Pfizer, Groton, CT Hydrophobic Drug Aggregates: Structure and Biology Eddy Arnold1, Yulia Frenkel2, Arthur D. Clark Jr.1, Kaylan Das2, Yuh-Hwa Wang3, Paul J. Lewi4 and Paul A. J. Janssen2, (1) Rutgers University, Piscataway, NJ, (2)Center for Advanced Biotechnology and Medicine, and Rutgers University, Piscataway, NJ, (3)UMDNJ, Piscataway, NJ, (4)Center for Molecular Design, Belgium In Silico Prediction of ADME Properties: Current Status of Predictive Models Terry Stouch, Editor-in-Chief, Hopewell, NJ

General Submissions